122 related articles for article (PubMed ID: 34990895)
1. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A; Guarneri V; Pascual T; Brasó-Maristany F; Sanfeliu E; Paré L; Schettini F; Martínez D; Jares P; Griguolo G; Dieci MV; Cortés J; Llombart-Cussac A; Conte B; Marín-Aguilera M; Chic N; Puig-Butillé JA; Martínez A; Galván P; Tsai YH; González-Farré B; Mira A; Vivancos A; Villagrasa P; Parker JS; Conte P; Perou CM
EBioMedicine; 2022 Jan; 75():103801. PubMed ID: 34990895
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.
Waks AG; Ogayo ER; Paré L; Marín-Aguilera M; Brasó-Maristany F; Galván P; Castillo O; Martínez-Sáez O; Vivancos A; Villagrasa P; Villacampa G; Tarantino P; Desai N; Guerriero J; Metzger O; Tung NM; Krop IE; Parker JS; Perou CM; Prat A; Winer EP; Tolaney SM; Mittendorf EA
JAMA Oncol; 2023 Jun; 9(6):835-840. PubMed ID: 37103927
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).
Villacampa G; Pascual T; Brasó-Maristany F; Paré L; Martínez-Sáez O; Cortés J; Ciruelos E; Martin M; Conte P; Carey LA; Fernandez A; Harbeck N; Marín-Aguilera M; Vivancos A; Curigliano G; Villagrasa P; Parker JS; Perou CM; Prat A; Tolaney SM
ESMO Open; 2024 Mar; 9(3):102388. PubMed ID: 38442452
[TBL] [Abstract][Full Text] [Related]
4. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Bueno-Muiño C; Echavarría I; López-Tarruella S; Roche-Molina M; Del Monte-Millán M; Massarrah T; Jerez Y; Ayala de la Peña F; García-Sáenz JÁ; Moreno F; Rodríguez-Lescure Á; Malón-Giménez D; Ballesteros García AI; Marín-Aguilera M; Galván P; Brasó-Maristany F; Waks AG; Tolaney SM; Mittendorf EA; Vivancos A; Villagrasa P; Parker JS; Perou CM; Paré L; Villacampa G; Prat A; Martín M
JAMA Oncol; 2023 Jun; 9(6):841-846. PubMed ID: 37103916
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M; Jares P; Sanfeliu E; Villacampa G; Hernández-Lllán E; Martínez-Puchol AI; Shankar S; González-Farré B; Waks AG; Brasó-Maristany F; Pardo F; Manning DK; Abery JA; Curaba J; Moon L; Gordon O; Galván P; Wachirakantapong P; Castillo O; Nee CM; Blasco P; Senevirathne TH; Sirenko V; Martínez-Sáez O; Aguirre A; Krop IE; Li Z; Spellman P; Metzger Filho O; Polyak K; Michaels P; Puig-Butillé JA; Vivancos A; Matito J; Buckingham W; Perou CM; Villagrasa-González P; Prat A; Parker JS; Paré L
ESMO Open; 2024 Mar; 9(3):102903. PubMed ID: 38452436
[TBL] [Abstract][Full Text] [Related]
6. Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
Pascual T; Fernandez-Martinez A; Tanioka M; Dieci MV; Pernas S; Gavila J; Guarneri V; Cortes J; Villagrasa P; Chic N; Vidal M; Adamo B; Muñoz M; Griguolo G; Llombart A; Conte P; Oliveira M; Conte B; Paré L; Galvan P; Carey LA; Perou CM; Prat A
Clin Cancer Res; 2021 Jun; 27(11):3116-3125. PubMed ID: 33632929
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Factors and Survival Outcomes of Patients With Early HER2+ Breast Cancer Treated With Trastuzumab in a Brazilian Public Reference Center: A Real-World Study.
Mattar A; Hegg R; Tayar DO; Rocha M; Terzian ALB; Oliveira RW; Julian GS; Gebrim LH
Clin Breast Cancer; 2023 Dec; 23(8):864-875.e7. PubMed ID: 37802752
[TBL] [Abstract][Full Text] [Related]
8. Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2-positive breast cancer patients: A machine learning approach.
Fanizzi A; Latorre A; Bavaro DA; Bove S; Comes MC; Di Benedetto EF; Fadda F; La Forgia D; Giotta F; Palmiotti G; Petruzzellis N; Rinaldi L; Rizzo A; Lorusso V; Massafra R
Cancer Med; 2023 Nov; 12(22):20663-20669. PubMed ID: 37905688
[TBL] [Abstract][Full Text] [Related]
9. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract][Full Text] [Related]
10. Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey.
Martínez-Sáez O; Cortés J; Ciruelos E; Marín-Aguilera M; González G; Paré L; Herrera A; Villagrasa-González P; Prat A; Martín M
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38653928
[TBL] [Abstract][Full Text] [Related]
11. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
Vathiotis IA; Moutafi MK; Divakar P; Aung TN; Qing T; Fernandez A; Yaghoobi V; El-Abed S; Wang Y; Guillaume S; Nuciforo P; Huober J; Di Cosimo S; Kim SB; Harbeck N; Gomez H; Shafi S; Syrigos KN; Fountzilas G; Sotiriou C; Pusztai L; Warren S; Rimm DL
Clin Cancer Res; 2021 Nov; 27(22):6156-6163. PubMed ID: 34465600
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract][Full Text] [Related]
13. Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer.
Kolarova I; Dusek L; Ryska A; Odrazka K; Dolezel M; Vanasek J; Melichar B; Petera J; Buchler T; Vosmik M; Petrakova K; Terarova P; Vilasova Z; Jarkovsky J
In Vivo; 2020; 34(6):3441-3449. PubMed ID: 33144452
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.
Atallah NM; Haque M; Quinn C; Toss MS; Makhlouf S; Ibrahim A; Green AR; Alsaleem M; Rutland CS; Allegrucci C; Mongan NP; Rakha E
Eur J Cancer; 2023 Dec; 195():113371. PubMed ID: 37897865
[TBL] [Abstract][Full Text] [Related]
15. Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Mazo C; Barron S; Mooney C; Gallagher WM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32369904
[TBL] [Abstract][Full Text] [Related]
16. Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.
Rubin E; Shan KS; Dalal S; Vu DUD; Milillo-Naraine AM; Guaqueta D; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256137
[TBL] [Abstract][Full Text] [Related]
17. A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer.
Lin C; Wu J; Lin L; Fei X; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Front Oncol; 2020; 10():1335. PubMed ID: 33042787
[No Abstract] [Full Text] [Related]
18. Comment on "Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases".
Yu T; Yang C; Li M
Br J Cancer; 2024 Apr; 130(6):893-894. PubMed ID: 38378876
[No Abstract] [Full Text] [Related]
19. Multi-omic machine learning predictor of breast cancer therapy response.
Sammut SJ; Crispin-Ortuzar M; Chin SF; Provenzano E; Bardwell HA; Ma W; Cope W; Dariush A; Dawson SJ; Abraham JE; Dunn J; Hiller L; Thomas J; Cameron DA; Bartlett JMS; Hayward L; Pharoah PD; Markowetz F; Rueda OM; Earl HM; Caldas C
Nature; 2022 Jan; 601(7894):623-629. PubMed ID: 34875674
[TBL] [Abstract][Full Text] [Related]
20. Txnrd1 as a prognosticator for recurrence, metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients.
Patwardhan RS; Rai A; Sharma D; Sandur SK; Patwardhan S
Heliyon; 2024 Mar; 10(6):e27011. PubMed ID: 38524569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
